Acknowledgements
KAR is a Scholar in Clinical Research of the Leukemia & Lymphoma Society.
Disclosure statement
KAR receives research funding from Genentech, AbbVie, and Novartis, consults for Genentech, AbbVie, Pharmacyclics, Janssen, AstraZeneca, BeiGene, LOXO@Lilly, and Alpine Immune Sciences. P.A.T. has served as a paid consultant for AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, Beigene, Genentech, Janssen, Lilly, and Merck and received honoraria from AbbVie, Adaptive Biotechnologies, AstraZeneca, Janssen and Merck.